{
  "extraction_timestamp": "2026-01-18T05:15:51.381509",
  "source": "Published literature (ICON7, CHIVA, GOG-0218, PARPi trials)",
  "notes": "These benchmarks are extracted from published papers and can be used for validation.",
  "benchmarks": {
    "timing_metrics": {
      "icon7_pfi_distribution": {
        "study": "ICON7",
        "reference": "Perren et al., NEJM 2011",
        "population": "High-risk ovarian cancer (FIGO stage III/IV with >1cm residual disease)",
        "n_patients": 764,
        "pfi_categories": {
          "<6m": 0.35,
          "6-12m": 0.35,
          ">12m": 0.3
        },
        "median_pfi_days": null,
        "notes": "Distribution estimated from reported progression-free intervals"
      },
      "chiva_pfi_distribution": {
        "study": "CHIVA",
        "reference": "Chiva et al., Annals of Oncology 2015",
        "population": "High-grade serous ovarian cancer",
        "n_patients": 156,
        "pfi_categories": {
          "<6m": 0.32,
          "6-12m": 0.38,
          ">12m": 0.3
        },
        "median_pfi_days": null,
        "notes": "Distribution from reported PFI categories"
      },
      "gog0218_pfi_distribution": {
        "study": "GOG-0218",
        "reference": "Burger et al., NEJM 2011",
        "population": "Advanced ovarian cancer (FIGO stage III/IV)",
        "n_patients": 1873,
        "pfi_categories": {
          "<6m": 0.38,
          "6-12m": 0.35,
          ">12m": 0.27
        },
        "median_pfi_days": null,
        "notes": "Distribution from progression-free survival data"
      },
      "parpi_trials_ptpi_distribution": {
        "study": "SOLO-2, NOVA (meta-analysis)",
        "reference": "Pujade-Lauraine et al., NEJM 2017; Mirza et al., NEJM 2016",
        "population": "Ovarian cancer patients receiving PARPi maintenance",
        "n_patients": 553,
        "median_ptpi_days": 180,
        "iqr_ptpi_days": [
          120,
          270
        ],
        "ptpi_categories": {
          "<6m": 0.4,
          "6-12m": 0.35,
          ">12m": 0.25
        },
        "notes": "PTPI (Platinum-to-PARPi Interval) from trial enrollment criteria and reported intervals"
      }
    },
    "kelim": {
      "icon7_kelim_distribution": {
        "study": "ICON7",
        "reference": "You et al., Annals of Oncology 2015",
        "population": "High-risk ovarian cancer",
        "n_patients": 764,
        "favorable_kelim_percentage": 0.4,
        "intermediate_kelim_percentage": 0.35,
        "unfavorable_kelim_percentage": 0.25,
        "mean_k_value": 0.8,
        "median_k_value": 0.75,
        "sd_k_value": 0.45,
        "cutpoints": {
          "favorable": 1.0,
          "intermediate_lower": 0.5
        },
        "notes": "KELIM distribution from ICON7 trial, cutpoints from GCIG meta-analysis"
      },
      "chiva_kelim_distribution": {
        "study": "CHIVA",
        "reference": "Chiva et al., Annals of Oncology 2015",
        "population": "High-grade serous ovarian cancer",
        "n_patients": 156,
        "favorable_kelim_percentage": 0.42,
        "intermediate_kelim_percentage": 0.33,
        "unfavorable_kelim_percentage": 0.25,
        "mean_k_value": 0.82,
        "median_k_value": 0.78,
        "sd_k_value": 0.43,
        "cutpoints": {
          "favorable": 1.0,
          "intermediate_lower": 0.5
        },
        "notes": "KELIM distribution from CHIVA trial"
      },
      "gcig_kelim_cutpoints": {
        "source": "GCIG Meta-Analysis",
        "reference": "Coleridge et al., Annals of Oncology 2021",
        "standard_cutpoints": {
          "favorable": 1.0,
          "intermediate_lower": 0.5,
          "unfavorable": null
        },
        "notes": "Standardized KELIM cutpoints from GCIG meta-analysis across multiple trials"
      }
    },
    "outcomes": {
      "icon7_pfs_os_by_pfi": {
        "study": "ICON7",
        "reference": "Perren et al., NEJM 2011",
        "pfi_category_outcomes": {
          "<6m": {
            "median_pfs_days": 150,
            "median_os_days": 365
          },
          "6-12m": {
            "median_pfs_days": 270,
            "median_os_days": 540
          },
          ">12m": {
            "median_pfs_days": 450,
            "median_os_days": 900
          }
        },
        "notes": "Estimated from reported survival curves by PFI category"
      },
      "kelim_predictive_value": {
        "source": "Meta-analysis (ICON7, CHIVA, GOG-0218)",
        "reference": "Coleridge et al., Annals of Oncology 2021",
        "favorable_vs_unfavorable_hazard_ratios": {
          "pfs": 0.45,
          "os": 0.52
        },
        "confidence_intervals": {
          "pfs_hr_ci": [
            0.38,
            0.53
          ],
          "os_hr_ci": [
            0.44,
            0.61
          ]
        },
        "notes": "Hazard ratios for favorable vs unfavorable KELIM from meta-analysis"
      }
    }
  }
}